[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account

How Personalized Is Multiple Myeloma Treatment and How Is That Changing? Introducing the Individual Risk Model for Myeloma

How Personalized Is Multiple Myeloma Treatment and How Is That Changing? Introducing the Individual Risk Model for Myeloma image

How Personalized Is Multiple Myeloma Treatment and How Is That Changing? Introducing the Individual Risk Model for Myeloma

Relapsed/Refractory Myeloma
event Oct 09, 2024 / 10:30AM - 11:30AM EDT
link icon facebook logo X logo linkedin logo reddit logo email icon

Event Description

As new targets and therapies are being discovered, the landscape of Multiple Myeloma treatment options is quickly evolving. How personalized are current treatment options, and how is that changing? Dr. Benjamin Diamond will join us to answer that question and give us an overview of IRMMa (Individual Risk Model for Myeloma) and it's implications for the future.

Schedule & Agenda

The panelist Cynthia Cahoon
Introductions
10:30 AM
Cynthia Cahoon

Cynthia introduces the agenda of the event and featured speaker Dr. Benjamin Diamond

The panelist Benjamin Diamond, MD
Presentation
10:35 AM
Benjamin Diamond, MD

Dr. Diamond talks about the landscape of Multiple Myeloma treatment

person
Questions and Answers
11:05 AM
Audience

Type your questions in the chat and we will answer them! 

Speakers & Moderators

The panelist Cynthia Cahoon
Cynthia Cahoon

Cynthia is a newborn ICU nurse by trade that has spent the last six years in the medical device industry educating nurses and doctors about devices that are new to their facility. In her spare time she enjoys hiking, traveling the world with her family, and creating Halloween animatronics for her annual front yard display. She has a passion for life-long learning and enjoys sharing what she learns with the people around her.

Read Bio
The panelist Benjamin Diamond, MD
Benjamin Diamond, MD

Dr. Diamond is a hematologist/oncologist who specializes in the treatment of plasma cell disorders including monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma. He completed fellowship at Memorial Sloan Kettering Cancer Center, spending a year as chief fellow, and is now an Assistant Professor at Sylvester Comprehensive Cancer Center is a member of the Myeloma Genomics Laboratory participating in translational research. His research interests include utilization of minimal residual disease (MRD)-guided approaches to clinical decision-making, maintenance therapy, and the genomics of multiple myeloma and secondary malignancies that occur in patients treated for multiple myeloma.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

newsletter icon

Get the latest thought leadership on your Multiple Myeloma delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Sanofi
Pfizer
Genentech
Regeneron
Adaptive

Follow Us

facebook instagram linkedin tiktok youtube